Outputs (20)

Mitochondrial markers predict recurrence, metastasis and Tamoxifen-resistance in breast cancer patients : early detection of treatment failure with companion diagnostics (2017)
Journal Article
Sotgia, F., Fiorillo, M., & Lisanti, M. (2017). Mitochondrial markers predict recurrence, metastasis and Tamoxifen-resistance in breast cancer patients : early detection of treatment failure with companion diagnostics. Oncotarget, 2017(8), 68730-68745. https://doi.org/10.18632/oncotarget.19612

Here, we used a data-mining and informatics approach to discover new biomarkers of resistance to hormonal therapy in breast cancer. More specifically, we investigated whether nuclear-encoded genes associated with mitochondrial biogenesis can be used... Read More about Mitochondrial markers predict recurrence, metastasis and Tamoxifen-resistance in breast cancer patients : early detection of treatment failure with companion diagnostics.

Mitoriboscins : mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast (2017)
Journal Article
Ozsvari, B., Fiorillo, M., Bonuccelli, G., Cappello, A., Frattaruolo, L., Sotgia, F., …Lisanti, M. (2017). Mitoriboscins : mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast. Oncotarget, 2017(8), 67457-67472. https://doi.org/10.18632/oncotarget.19084

The “endo-symbiotic theory of mitochondrial evolution” states that mitochondrial organelles evolved from engulfed aerobic bacteria, after millions of years of symbiosis and adaptation. Here, we have exploited this premise to design new antibiotics an... Read More about Mitoriboscins : mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast.

ESPEN expert group recommendations for action against cancer-related malnutrition (2017)
Journal Article
Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P., Deutz, N., …Weimann, A. (2017). ESPEN expert group recommendations for action against cancer-related malnutrition. Clinical Nutrition, 36(5), 1187-1196. https://doi.org/10.1016/j.clnu.2017.06.017

Patients with cancer are at particularly high risk for malnutrition because both the disease and its treatments threaten their nutritional status. Yet cancer-related nutritional risk is sometimes overlooked or under-treated by clinicians, patients, a... Read More about ESPEN expert group recommendations for action against cancer-related malnutrition.

Targeting hypoxic cancer stem cells (CSCs) with Doxycycline : implications for optimizing anti-angiogenic therapy (2017)
Journal Article
implications for optimizing anti-angiogenic therapy. Oncotarget, 2017(8), 56126-56142. https://doi.org/10.18632/oncotarget.18445

Here, we report new mechanistic insight into how chronic hypoxia increases ‘stemness’ in cancer cells. Using chemical inhibitors, we provide direct experimental evidence that ROS production and mitochondrial biogenesis are both required for the hypox... Read More about Targeting hypoxic cancer stem cells (CSCs) with Doxycycline : implications for optimizing anti-angiogenic therapy.

Vitamin C and Doxycycline : a synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs) (2017)
Journal Article
De Francesco, E., Bonuccelli, G., Maggiolini, M., Sotgia, F., & Lisanti, M. (2017). Vitamin C and Doxycycline : a synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs). Oncotarget, 2017(8), 67269-67286. https://doi.org/10.18632/oncotarget.18428

Here, we developed a new synthetic lethal strategy for further optimizing the eradication of cancer stem cells (CSCs). Briefly, we show that chronic treatment with the FDA-approved antibiotic Doxycycline effectively reduces cellular respiration, by... Read More about Vitamin C and Doxycycline : a synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs).

Hodgkin lymphoma : a complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment (2017)
Journal Article
Mikkilineni, L., Whitaker-Menezes, D., Domingo-Vidal, M., Sprandio, J., Avena, P., Cotzia, P., …Martinez-Outschoorn, U. (2017). Hodgkin lymphoma : a complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment. Seminars in Oncology, 44(3), 218-225. https://doi.org/10.1053/j.seminoncol.2017.10.003

Background Twenty percent of patients with classical Hodgkin Lymphoma (cHL) have aggressive disease defined as relapsed or refractory disease to initial therapy. At present we cannot identify these patients pre-treatment. The microenvironment is v... Read More about Hodgkin lymphoma : a complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.

Current and prospective pharmacotherapies for the treatment of pleural mesothelioma (2017)
Journal Article
Bakker, E., Guazzelli, A., Krstic-Demonacos, M., Lisanti, M., Sotgia, F., & Mutti, L. (2017). Current and prospective pharmacotherapies for the treatment of pleural mesothelioma. Expert Opinion on Orphan Drugs, 5(6), 455-465. https://doi.org/10.1080/21678707.2017.1325358

Introduction: Mesothelioma is a rare asbestos-linked cancer with an expected incidence peak between 2015–2030. Therapies remain ineffective, thus developing and testing novel treatments is important for both oncologists and researchers. Areas co... Read More about Current and prospective pharmacotherapies for the treatment of pleural mesothelioma.

Mitochondrial “power” drives tamoxifen resistance : NQO1 and GCLC are new therapeutic targets in breast cancer (2017)
Journal Article
Fiorillo, M., Sotgia, F., Sisci, D., Cappello, A., & Lisanti, M. (2017). Mitochondrial “power” drives tamoxifen resistance : NQO1 and GCLC are new therapeutic targets in breast cancer. Oncotarget, 2017(8), 20309-20327. https://doi.org/10.18632/oncotarget.15852

Here, we identified two new molecular targets, which are functionally sufficient to metabolically confer the tamoxifen-resistance phenotype in human breast cancer cells. Briefly, ~20 proteins were first selected as potential candidates, based on u... Read More about Mitochondrial “power” drives tamoxifen resistance : NQO1 and GCLC are new therapeutic targets in breast cancer.

Anti-CTLA-4 therapy for malignant mesothelioma (2017)
Journal Article
Guazzelli, A., Bakker, E., Krstic-Demonacos, M., Lisanti, M., Sotgia, F., & Mutti, L. (2017). Anti-CTLA-4 therapy for malignant mesothelioma. Immunotherapy, 9(3), 273-280. https://doi.org/10.2217/imt-2016-0123

Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This... Read More about Anti-CTLA-4 therapy for malignant mesothelioma.

NADH autofluorescence, a new metabolic biomarker for cancer stem cells : identification of Vitamin C and CAPE as natural products targeting “stemness” (2017)
Journal Article
Bonuccelli, G., De Francesco, E., de Boer, R., Tanowitz, H., & Lisanti, M. (2017). NADH autofluorescence, a new metabolic biomarker for cancer stem cells : identification of Vitamin C and CAPE as natural products targeting “stemness”. Oncotarget, 2017(8), 20667-20678. https://doi.org/10.18632/oncotarget.15400

Here, we assembled a broad molecular “tool-kit” to interrogate the role of metabolic heterogeneity in the propagation of cancer stem-like cells (CSCs). First, we subjected MCF7 cells to “metabolic fractionation” by flow cytometry, using fluorescent... Read More about NADH autofluorescence, a new metabolic biomarker for cancer stem cells : identification of Vitamin C and CAPE as natural products targeting “stemness”.